A1110UAlternative Names: BW 1110U81
Latest Information Update: 26 Jul 1994
At a glance
- Originator Burroughs Wellcome
- Class Antivirals; Hydrazones
- Mechanism of Action Ribonucleotide reductase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Herpes simplex virus infections; Varicella zoster virus infections